Abstract
Understanding the cardiovascular side effects of cancer therapies is essential in preclinical research. We present a step-by-step protocol to evaluate cardiovascular function in triiodothyronine-treated, tumor-bearing mice using non-invasive electrocardiogram (ECG) recordings. The steps involve acclimating awake mice to recording towers, obtaining ECG traces without anesthesia, and assessing cardiac parameters. This approach enables reliable monitoring of treatment-induced cardiac effects and supports cardiovascular safety evaluation during preclinical cancer drug development. For complete details on the use and execution of this protocol, please refer to Yang et al.(1).